Grapheal, a French developer of graphene-enhanced biosensors, has recently raised the equivalent of $3 Million usd to go towards their new Covid-19 testing technology and wound surveillance system.
Most notably, the funds are slated to go towards TestNPass, their rapid Covid-19 test which can detect the virus in 5 minutes or less. Their second technology that will benefit from this raising is the WoundLAB, a graphene-based patch that can record and store critical information about long-term wounds on the human body. The information can be collected with a smartphone, which makes this accessible and easy.
Dr. Vincent Bouchiat, CEO of Grapheal stated that the medical applications of graphene are yet to be fully realized, and with this round of funding their first product will reach the market within the year, helped greatly by the funding.